Leader editor capable of improving editing activity, gene editing system comprising leader editor and application of leader editor

By fusing SSAPs with napDNAbp and reverse transcriptase in the lead editing system, the resulting fusion protein improves gene editing efficiency and accuracy, solving the problem of insufficient efficiency and accuracy in existing lead editing systems and achieving more efficient gene editing results.

CN118979027APending Publication Date: 2024-11-19INNOVEC BIOTHERAPEUTICS
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411034921.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-16
Filing Date
2024-07-30
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing lead editing systems have shortcomings in gene editing efficiency and accuracy, particularly high insertion/deletion rates and significant off-target effects, and the role of SSAPs in lead editing has not been fully utilized.

Method used

A fusion protein is formed by fusing single-stranded DNA annealing protein (SSAP) with a nucleic acid programmable DNA binding protein (napDNAbp) and reverse transcriptase to improve the editing efficiency of the leader editor. Specifically, SSAP is selected from different families of eukaryotes, prokaryotes and bacteriophages, such as RAD52, ERF, Sak3, etc. The fusion protein contains a Cas9 variant and a P2A self-cleaving peptide.

Benefits of technology

At endogenous sites in mCherry reporter cell lines and HEK293T cells, PE2-SSAPs improved editing efficiency to 1.5-2.5 times that of conventional PE2, maintained high accuracy, significantly improved homologous recombination repair efficiency, and reduced insertion/deletion rates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979027A_ABST
    Figure CN118979027A_ABST
Patent Text Reader

Abstract

The invention provides a leader editor capable of improving editing activity, a gene editing system comprising the leader editor and application of the leader editor. Specifically, the present disclosure provides a leader editor wherein the leader editor comprises a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase, and a single stranded DNA annealing protein (SSAP). In the constructed pilot editor or gene editing system, different SSAPs are fused with a PE2 system which does not cause DNA double-chain breakage (PE2-SSAPs), so that the editing efficiency of the PE2 system is improved, and meanwhile, high accuracy is kept.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority and related applications

[0002] The present disclosure claims priority to Chinese patent application 202311031684.7 filed on August 16, 2023, entitled “A lead editor with enhanced editing activity, a gene editing system comprising the same and uses thereof”, and all contents of the application including the appendix are incorporated into the present disclosure as a reference. Technical Field

[0003] The present disclosure relates to a lead editor with improved editing activity, a gene editing system and uses thereof, and belongs to the technical field of gene editing. Background Art

[0004] Prime editing (PE, or guide editing) is a gene editing method that can perform targeted insertions, deletions, and base substitutions (conversions). Prime editing can achieve conversions between all 12 bases without a DNA template, and can also achieve efficient and accurate insertion or deletion of small fragments. Compared with the CRISPR / Cas system, it will not cause DNA double-strand breaks, showing higher safety and great scientific research and clinical application value.

[0005] However, similar to the CRISPR / Cas system, prime editing requires the presence of an endonuclease and a guide RNA, although both components are often significantly modified. Instead of using the traditional Cas9, a Cas9 variant that makes a nick in the DNA instead of creating a double-strand break (called a Cas9 nickase) is introduced, fused to a reverse transcriptase. This modified Cas9 fusion protein is called a prime editor.

[0006] To date, several lead editors and their iterations have been developed that demonstrate insertions, deletions, and base conversions with moderate editing efficiencies (as disclosed in WO2020 / 191234A1). Despite the improvements in gene targeting of engineered Cas9 variants, lead editing still faces unresolved challenges, with shortcomings including low efficiency, high rates of insertions and deletions (Indels) (i.e., unwanted insertions or deletions caused by non-homologous end joining), off-target nicking sites on the other chain, and deleterious cellular effects.

[0007] Homologous recombination is a key link in DNA repair and replication. The two most important steps in the recombination process are homologous DNA pairing and strand exchange between paired DNA. RecA family proteins are core recombinases that play the role of double-stranded DNA pairing and strand exchange in the homologous recombination process of prokaryotes. Although recombinases such as RecA or its eukaryotic homologous protein RAD51 are the most important proteins in homologous recombination, more and more studies have found that some proteins that are independent of RecA in evolution play an important role in homologous recombination. Single-stranded DNA-annealing proteins (SSAPs) are a type of recombinase that is different from RecA family proteins. SSAPs originally originated from bacteriophages and later spread to prokaryotes and eukaryotes with the interaction between bacteriophages and hosts. SSAPs bind to the 3' end region of single-stranded DNA caused by nucleases during homologous recombination, and promote strand exchange between homologous DNA by assisting the pairing of complementary single-stranded regions. Compared with RecA family recombinases, SSAPs have been shown to promote recombination between shorter DNA with large sequence differences. Unlike the conservative RecA family recombinases, SSAPs recombinases exhibit huge sequence diversity. SSAPs are classified according to sequence similarity and evolutionary relationships. Family proteins such as RecT, RAD52, ERF, Sak3 and Gp2.5 have been identified (Iyer, Lakshminarayan M et al. "Classification and evolutionary history of the single-strand annealing proteins, RecT, Redbeta, ERF and RAD52." BMC genomics vol. 3 (2002): 8.; Steczkiewicz, Kamil et al. "Expanding Diversity of Firmicutes Single-Strand Annealing Proteins: A Putative Role of Bacteriophage-Host Arms Race." Frontiers in microbiology vol. 12 644622. 20Apr. 2021.).

[0008] Previous studies have shown (Tran, Ngoc-Tung et al. "Enhancement of Precise Gene Editing by the Association of Cas9 With Homologous Recombination Factors." Frontiers in genetics vol.10365.30Apr.2019.; Microbial single-strand annealing proteins enable CRISPR gene-editing tools with improved knock-in efficienciesand reduced off-target effects, Nucleic Acids Research, 2021, Vol.49, No.6e36; doi:10.1093 / nar / gkaa1264) that the fusion of recombinase and SSAPs with Cas9 or nCas9 (Cas9 nickase) can improve the efficiency of homologous recombination repair (HDR) mediated by the CRISPR / Cas system. However, SSAP needs to be fused with bacteriophage MS2 coat protein (MCP) or single-chain antibody (scFv), specially designed gRNA, added MS2 stem-loop structure, or fused and expressed tandem peptide epitope (Suntag) on ​​Cas9 protein, etc., which is complicated. In addition, it is still unknown what role recombinase and SSAP play in existing lead editing.

[0009] However, there is still a need for improved prime editing complexes to increase the editing efficiency of target genes. Summary of the invention

[0010] Problem that the invention aims to solve

[0011] For example, WO2020 / 191234A1 discloses a lead editing system, but its editing efficiency still needs to be improved. In the prior art, single-stranded DNA annealing protein has been fused to Cas9 to improve the efficiency of homologous recombination repair mediated by the CRISPR / Cas system, but the effect of single-stranded DNA annealing protein on the lead editing system is still unknown. The purpose of this disclosure is to improve the efficiency of the lead editing system.

[0012] Solutions for solving problems

[0013] [1]. A lead editor, wherein the lead editor comprises a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase and a single-stranded DNA annealing protein (SSAP).

[0014] [2] The lead editor according to [1], wherein the SSAP is an SSAPP from a eukaryote, a prokaryote and / or a bacteriophage; and / or the SSAP is an SSAP from the RecT, RAD52, ERF, Sak3 and / or Gp2.5 family.

[0015] [3] The lead editor according to [1] or [2], wherein the SSAP is from Homo sapiens, Arcobacter porcinus, Salmonella enterica, Vibriophage, Delftia acidovorans or Roseburia; and / or the SSAP is from the RAD52 family, the Sak3 family or the ERF family.

[0016] [4] The lead editor according to any one of [1] to [3], wherein the SSAP comprises an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 6, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 1 to 6.

[0017] [5] The lead editor according to any one of [1] to [4], wherein the napDNAbp has nickase activity;

[0018] Optionally, the napDNAbp is selected from a catalytically impaired Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, Argonaute protein or a variant thereof;

[0019] Preferably, the napDNAbp is Cas9 nickase (nCas9) or a variant thereof;

[0020] More preferably, the napDNAbp comprises the amino acid sequence shown in SEQ ID NO:7, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:7.

[0021] [6]. The lead editor according to any one of [1] to [5], wherein the reverse transcriptase comprises an amino acid sequence as shown in SEQ ID NO:8, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:8.

[0022] [7] The lead editor according to any one of [1] to [6], wherein the napDNAbp, reverse transcriptase and SSAP form a fusion protein, or the napDNAbp and reverse transcriptase form a fusion protein;

[0023] Optionally, the fusion protein comprises the structure NH2-[napDNAbp]-[reverse transcriptase]-[SSAP]-COOH; or NH2-[reverse transcriptase]-[napDNAbp]-[SSAP]-COOH;

[0024] Optionally, the fusion protein comprises the structure NH2-[napDNAbp]-[reverse transcriptase]-COOH; or NH2-[reverse transcriptase]-[napDNAbp]-COOH.

[0025] [8] The lead editor according to [7], wherein a 2A self-cleavage peptide is contained between the napDNAbp and the SSAP or between the reverse transcriptase and the SSAP;

[0026] Preferably, a P2A self-cleavage peptide is included between the napDNAbp and SSAP or between the reverse transcriptase and SSAP.

[0027] [9] The lead editor according to any one of [1] to [8], wherein the lead editor comprises one or more of the following sequences:

[0028] (i) an amino acid sequence as shown in any one of SEQ ID NOs: 10 to 15;

[0029] (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15, and which retains the activity of the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15;

[0030] (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of any one of SEQ ID NOs: 10 to 15, and which retains the activity of the amino acid sequence of any one of SEQ ID NOs: 10 to 15; or,

[0031] (iv) an amino acid sequence encoded by a nucleotide sequence, which hybridizes with a polynucleotide sequence encoding the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15 under stringent conditions, and the amino acid sequence retains the activity of the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15, wherein the stringent conditions are medium stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

[0032]

[10] A gene editing system, wherein the gene editing system comprises:

[0033] (i) the lead editor described in any one of [1] to [9]; and

[0034] (ii) Prime editing guide RNA (pegRNA).

[0035]

[11] . An isolated polynucleotide, wherein the polynucleotide encodes a lead editor as described in any one of [1] to [9] or encodes a gene editing system as described in

[10] .

[0036]

[12] . A vector comprising the polynucleotide described in

[11] .

[0037]

[13] A cell comprising one or more of the following:

[0038] (a) the lead editor as described in any one of [1] to [9];

[0039] (b) The gene editing system as described in

[10] ;

[0040] (c) the polynucleotide described in

[11] ; and

[0041] (d) The vector as described in

[12] .

[0042]

[14] . A pharmaceutical composition comprising one or more of the following (A) to (E):

[0043] (A) the lead editor described in any one of [1] to [9];

[0044] (B) The gene editing system as described in

[10] ;

[0045] (C) the polynucleotide described in

[11] ;

[0046] (D) the vector described in

[12] ; and

[0047] (E) the cell as described in

[13] ;

[0048] And, optionally, a pharmaceutically acceptable carrier.

[0049]

[15] A kit comprising one or more of the following:

[0050] (A) the lead editor described in any one of [1] to [9];

[0051] (B) The gene editing system as described in

[10] ;

[0052] (C) the polynucleotide described in

[11] ;

[0053] (D) the vector described in

[12] ; and

[0054] (E) Cells as described in

[13] .

[0055]

[16] . A method for modifying a target nucleic acid, the method comprising the step of contacting the target nucleic acid with a lead editor as described in any one of [1] to [9], a gene editing system as described in

[10] , a polynucleotide as described in

[11] , a vector as described in

[12] , a cell as described in

[13] , a pharmaceutical composition as described in

[14] , or a kit as described in

[15] .

[0056]

[17] . Use of the lead editor described in any one of [1] to [9], the gene editing system described in

[10] , the polynucleotide described in

[11] , the vector described in

[12] or the cell described in

[13] in the preparation of a reagent for modifying a target nucleic acid.

[0057]

[18] . A method for preventing and / or treating a disease associated with or caused by a gene mutation, comprising the step of administering to a subject a therapeutically effective amount of a lead editor as described in any one of [1] to [9], a gene editing system as described in

[10] , a polynucleotide as described in

[11] , a vector as described in

[12] , a cell as described in

[13] , a pharmaceutical composition as described in

[14] , or a kit as described in

[15] .

[0058]

[19] . Use of the lead editor described in any one of [1] to [9], the gene editing system described in

[10] , the polynucleotide described in

[11] , the vector described in

[12] , the cell described in

[13] , the pharmaceutical composition described in

[14] or the kit described in

[15] in the preparation of a drug for treating a disease related to or caused by a gene mutation.

[0059]

[20] . Use of single-stranded DNA annealing protein (SSAP) for improving the editing activity of a fusion protein, wherein the fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase.

[0060]

[21] . A method for improving the editing activity of a fusion protein, comprising the step of co-administering the fusion protein with a single-stranded DNA annealing protein (SSAP), wherein the fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase.

[0061] Effects of the Invention

[0062] In the lead editor or gene editing system constructed by the present disclosure, different SSAPs are fused with the PE2 system that does not cause DNA double-strand breaks (PE2-SSAPs). The editing efficiency of PE2-SSAP detected in the mCherry reporter cell line is about 1.5-2.5 times that of the traditional PE2, and at the endogenous sites EMX1 and HEK3 in the cell, the editing efficiency is 2.0-4.2 and 1.2-2.1 times that of PE2, respectively. While improving the editing efficiency of the PE2 system, PE2-SSAPs still retain the advantage of high accuracy of PE2. Therefore, PE2-SSAPs will greatly enhance the scope of application of the PE2 system and have broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 .Construction of mCherry-reporter cell line and PE2-SSAPs system. Figure 1 A in the figure shows the construction of the mCherry-reporter cell line. The sequence encoding mCherry contains the protospacer recognized by pegRNA and the PAM sequence NGG recognized by nCas9. Under normal circumstances, the mCherry reading frame undergoes a one-base frameshift and is not expressed. If the PE2, PE2-RecA or PE2-SSAPs system is edited and a base is inserted, the expression of mCherry will be activated, and the efficiency of the editing tool can be determined by flow cytometry analysis. Figure 1 B in the figure shows the structure of an exemplary pegRNA, whose spacer sequence recognizes the original spacer on the reporter cell line, and the 16bp reverse transcription template (RT template / DNA synthesis template) contains a base insertion, thereby restoring the reading frame of mCherry and activating mCherry expression. Figure 1 C in the figure shows the structure of PE2-RecA and PE2-SSAPs. RecA or different SSAPs are expressed by fusion with P2A to the C-terminus of the PE2 system.

[0064] Figure 2.Flow cytometric analysis showed that PE2-SSAPs significantly increased the efficiency of PE2 in activating mCherry. Figure 2 A in the figure shows a schematic diagram of flow cytometry analysis to detect the expression of mCherry in reporter cell lines activated by PE2, PE2-RecA and PE2-SSAPs. mCherry is not expressed in untransfected cells, the activation ratio of PE2 is about 22%, and that of PE2-RecA is about 30%. Compared with PE2 or PE2-RecA, the activation ratio of PE2-SSAPs is significantly increased. Figure 2 B in the figure shows the quantitative statistical graph of the activation efficiency of mCherry expression by PE2, PE2-RecA and PE2-SSAPs, and it can be seen that the activation efficiency is increased from about 20% to about 40% at the highest. Figure 2 C in the figure shows the activation ratio of PE2-SSAPs relative to PE2, which is generally 1.42-1.87 times that of PE2.

[0065] Figure 3 .The results of targeted amplicon high-throughput sequencing showed that the editing efficiency of PE2-SSAPs was significantly improved. Figure 3 Panel A shows the sequence at the targeted site in an untreated mCherry reporter cell line. Figure 3 B in the figure shows the editing of the target site after the mCherry reporter cell line was transfected with the PE2 system. The box shows the correct editing, that is, a base A is inserted at the first position downstream of the nCas9 restriction site (+1 site), and a G to T conversion occurs at the sixth base downstream of the restriction site (+6 site). Figure 3 C to Figure 3 H in the figure shows a schematic diagram of the mCherry reporter cell line when this target site is edited by PE2-SSAPs, and it can be seen that its editing efficiency is increased from 17% to a maximum of 45%.

[0066] Figure 4 .The results of targeted amplicon high-throughput sequencing showed the high efficiency and accuracy of PE2-SSAPs. Figure 4 A in the figure shows that the editing efficiency of PE2 is about 19%, and the editing efficiencies of PE2-SSAPs are 32%, 35%, 28%, 45%, 36% and 43%, respectively. At the same time, the proportion of insertions and deletions (Indels) caused by PE2-SSAPs is similar to that of PE2, retaining the advantage of high accuracy of PE2. Figure 4 B in the figure shows the statistical results of the editing efficiency of PE2-SSAPs relative to PE2, showing that its overall editing efficiency is 1.50-2.45 times that of PE2.

[0067] Figure 5 .PE2-SSAPs significantly improved the editing efficiency of endogenous sites in HEK293T cells. Figure 5 A in the figure shows that the PE2 system targets the EMX1 site, generating a G to C mutation (+1Gto C) at the first base downstream of the nCas9 restriction site (+1site). Figure 5 B in the figure shows that the PE2 system targets the HEK3 site, generating a T to A mutation (+1T to A) at the first base downstream of the nCas9 restriction site (+1 site). It should be noted that there is a SNP site near this site (+9 site) in HEK293T, which has no effect when calculating the editing efficiency. Figure 5 Figure C shows the editing statistics of the EMX1 site. The editing efficiency of PE2-SSAPs increased from 0.5% of PE2 to a maximum of 2.1%. Its overall editing efficiency is 2-4 times that of PE2, and the proportion of Indels remains at an extremely low level. Figure 5 D in the figure shows the editing statistics of HEK3 sites. The editing efficiency of PE2-SSAPs increased from 1.4% of PE2 to a maximum of 2.9%. Its overall editing efficiency was 1.2-2.1 times that of PE2, and the proportion of Indels remained at an extremely low level. DETAILED DESCRIPTION

[0068] Various exemplary embodiments, features and aspects of the present disclosure will be described in detail below. The word "exemplary" used herein means "used as an example, embodiment or illustrative". Any embodiment described herein as "exemplary" is not necessarily to be interpreted as being superior or better than other embodiments.

[0069] In addition, in order to better illustrate the present disclosure, numerous specific details are given in the following specific embodiments. It should be understood by those skilled in the art that the present disclosure can also be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present disclosure.

[0070] Unless otherwise stated, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in this disclosure should be understood to include the inevitable systematic errors in industrial production.

[0071] As used in the present disclosure, the meaning of “may” includes both performing a certain process and not performing a certain process.

[0072] As used in this disclosure, references to "some specific / preferred embodiments," "other specific / preferred embodiments," "embodiments," etc., mean that the specific elements (e.g., features, structures, properties, and / or characteristics) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner.

[0073] As used in the present disclosure, a numerical range expressed using “a value A to a value B” means a range including the endpoints A and B.

[0074] As used in the present disclosure, the terms "nucleic acid" and "nucleic acid molecule" refer to compounds comprising a core base and an acidic portion, such as a polymer of a nucleoside, a nucleotide or a nucleotide. Typically, a polymeric nucleic acid, such as a nucleic acid molecule comprising three or more nucleotides is a linear molecule in which adjacent nucleotides are interconnected by a phosphodiester bond. In some embodiments, "nucleic acid" refers to a single nucleic acid residue (such as a nucleotide and / or a nucleoside). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used in the present disclosure, the terms "oligonucleotide" and "polynucleotide" are used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides).

[0075] As used in this disclosure, the terms "polypeptide," "peptide," and "protein" are used interchangeably herein and are amino acid polymers of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also includes amino acid polymers that have been modified (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component).

[0076] As used in this disclosure, "isolated" means changed or removed from its natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated", but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-natural environment such as, for example, a host cell.

[0077] As used in the present disclosure, "fusion protein" refers to a hybrid polypeptide comprising protein domains from at least two different proteins. A protein may be located at the amino-terminal (N-terminal, N-terminal) portion or the carboxyl-terminal (C-terminal, C-terminal) protein of the fusion protein, thereby forming an "amino-terminal fusion protein" or a "carboxyl-terminal fusion protein", respectively. Any protein provided herein can be produced by any method known in the art. For example, the protein provided herein can be produced via recombinant protein expression and purification, which is particularly suitable for fusion proteins comprising peptide linkers. Methods for recombinant protein expression and purification are well known, and include those described in: Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)), the entire contents of which are incorporated herein by reference.

[0078] As used in this disclosure, the term "CRISPR" refers to Clustered regularly interspaced short palindromic repeats, which are derived from the immune system of microorganisms.

[0079] As used in the present disclosure, the term "Cas protein" refers to CRISPR-associated protein. The Cas protein and the CRISPR sequence together constitute the CRISPR / Cas system. The Cas protein has a functional domain related to the nuclease and cuts the target sequence at a specific position by recognizing PAM (protospacer adjacent motif).

[0080] As used in the present disclosure, the term "Cas9" or "Cas9 domain" refers to an RNA-guided nuclease comprising a Cas9 protein or a fragment thereof (e.g., a protein comprising an active, inactive or partially active DNA cleavage domain of Cas9, and / or a binding domain of gRNA Cas9). Cas9 nucleases are sometimes also referred to as CRISPR-associated nuclease 9. As previously described, CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). The CRISPR cluster contains numerous short and conserved repeat regions and spacers. The CRISPR cluster is transcribed and processed into pre-crRNA. In the type II CRISPR / cas9 system, transcoded small RNA (tracrRNA), endogenous ribonuclease 3 (RNase III), and Cas9 protein are required for the correct processing of pre-crRNA. TracrRNA serves as a guide for ribonuclease 3 to assist in the processing of pre-crRNA. Subsequently, Cas9 / crRNA / tracrRNA endonucleases a linear or circular dsDNA target complementary to the spacer sequence. The target strand that is not complementary to crRNA is cut by endonucleolytic cutting. In nature, DNA binding and cutting usually require proteins and two RNAs. However, a single guide RNA (sgRNA) can be engineered to integrate various aspects of crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M. et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Cas9 recognizes a short motif in the CRISPR repeat sequence (PAM or protospacer adjacent motif) to help distinguish self from non-self.Cas9 nuclease sequence and structure are well known to those skilled in the art (see, e.g., "Complete genome sequence of an M1 strain of Streptococcus pyogenes." Ferretti et al., Proc. Natl. Acad. Sci. USA 98:4658-4663 (2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E. et al., Nature 471:602-607 (2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M. et al., Science 337:816-821 (2012)). Cas9 orthologs have been described in various species, including but not limited to Streptococcus pyogenes and Streptococcus thermophilus. Other suitable Cas9 nucleases and sequences will be apparent to those skilled in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from organisms and loci disclosed in Chylinski, Rhun and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.

[0081] Nuclease-inactivated Cas9 proteins are interchangeably referred to as "dCas9" proteins (nuclease-"dead" Cas9 or Cas9 without nuclease activity) or catalytically inactivated Cas9. It is known to produce Cas9 proteins (or fragments thereof) with inactive DNA cleavage domains (see, e.g., Jinek et al., Science. 337: 816-821 (2012); Qi et al. "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression" (2013) Cell. 28; 152 (5): 1173-83). For example, it is known that the DNA cleavage domain of Cas9 includes two subdomains, the HNH nuclease subdomain and the RuvC subdomain. The HNH subdomain cuts the strand complementary to the gRNA, while the RuvC subdomain cuts the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, mutations D10A and H840A completely inactivate the nuclease activity of Streptococcus pyogenes Cas9 (Jinek et al., Science. 337: 816-821 (2012); Qi et al., Cell. 28: 152 (5): 1173-83 (2013)). Based on the knowledge in the art, additional suitable nuclease-free Cas9 domains will be apparent to those skilled in the art. Such additional exemplary suitable nuclease-free Cas9 domains include, but are not limited to, D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., Nature Biotechnology. 2013; 31 (9): 833-838).

[0082] As used in the present disclosure, the term "nickase" refers to a Cas9 in which one of the two nuclease domains is inactivated. This enzyme can only cut one strand of the target DNA. The Cas9 nickase is capable of cutting one strand of double-stranded DNA. The Cas9 nickase can be generated by introducing an inactivating mutation into the HNH subdomain or the RuvC subdomain. For example, an inactivating mutation (D10A) can be introduced into the RuvC domain of Streptococcus pyogenes Cas9, while the HNH domain remains active, i.e., the residue at position 840 remains as histidine. Such Cas9 variants can generate single-stranded DNA breaks (nicks) at specific positions based on the target sequence determined by the gRNA. Those skilled in the art can identify the catalytic residues in the RuvC and HNH domains of any known Cas9 protein and introduce inactivating mutations to generate corresponding dCas9 or nCas9.

[0083] Similarly, for other Cas proteins, those skilled in the art can obtain the corresponding Cas proteins without nuclease activity and the nicking enzyme that cuts one strand of double-stranded DNA in the same manner.

[0084] As used in the present disclosure, the terms "nucleic acid programmable nucleotide binding domain", "nucleic acid programmable DNA-binding protein (napDNAbp)" refer to a protein that binds to a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., gRNA), which guides the napDNAbp to a specific nucleic acid sequence, for example, by hybridizing with a target nucleic acid sequence. For example, the Cas9 protein can be bound to a guide RNA that guides the Cas9 protein to a specific DNA sequence that is complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, such as a nuclease-active Cas9, a Cas9 nickase (nCas9), or a nuclease-free Cas9 (dCas9). Examples of nucleic acid programmable DNA binding proteins include, but are not limited to, Cas9 (e.g., dCas9 and nCas9), CasX, CasY, Cpf1, C2c1, C2c2, C2c3, and Argonaute protein (AGO). However, it should be understood that nucleic acid programmable DNA binding proteins also include nucleic acid programmable proteins that bind RNA. For example, the napDNAbp can be bound to a nucleic acid that guides the napDNAbp to the RNA.Other nucleic acid programmable DNA binding proteins are also within the scope of the present disclosure, although they may not be specifically described in the present disclosure.

[0085] As used in the present disclosure, the term "protospacer" refers to a sequence (about 20bp) adjacent to a PAM (protospacer adjacent motif) sequence in DNA. The protospacer shares the same sequence with the spacer sequence of the guide RNA. The guide RNA anneals with the complementary sequence of the protospacer on the target DNA (specifically, one of its strands, i.e., the "target strand" of the target DNA sequence relative to the "non-target strand"). In order for Cas9 to work, a specific protospacer adjacent motif (PAM) is also required, which varies with the bacterial species of the Cas9 gene. The most commonly used Cas9 nuclease derived from Streptococcus pyogenes recognizes the PAM sequence of NGG on the non-target strand, which is directly located downstream of the genomic DNA target sequence. The technician will understand that the literature in the prior art sometimes refers to the "protospacer" as an approximately 20-nt target-specific guide sequence on the guide RNA itself, rather than referring to it as a "spacer". Therefore, in some cases, the term "protospacer" as used herein can be used interchangeably with the term "spacer". The context surrounding the appearance of "protospacer" or "spacer" will help inform the reader whether the term refers to the gRNA or the DNA target.

[0086] As used in the present disclosure, the term "protospacer adjacent motif" or "PAM" refers to a DNA sequence of about 2-6 base pairs that is an important targeting component of the Cas9 nuclease. Typically, the PAM sequence is located on either chain and is located downstream of the Cas9 cleavage site in the 5' to 3' direction. The classical PAM sequence (i.e., the PAM sequence associated with the Cas9 nuclease of Streptococcus pyogenes or SpCas9) is 5'-NGG-3', where "N" is any nucleobase followed by two guanine ("G") nucleobases. Different PAM sequences may be associated with different Cas9 nucleases or equivalent proteins from different organisms. In addition, any given Cas9 nuclease, such as SpCas9, may be modified to alter the PAM specificity of the nuclease so that the nuclease recognizes an alternative PAM sequence.

[0087] As used in the present disclosure, the term "spacer sequence" or "spacer" in relation to a guide RNA or pegRNA refers to a portion of about 20 nucleotides of a guide RNA or pegRNA that comprises a nucleotide sequence complementary to the original spacer in the target DNA sequence. The spacer sequence anneals with the original spacer to form a ssRNA / ssDNA hybrid structure at the target site and a corresponding R-loop ssDNA structure of an endogenous DNA chain complementary to the original spacer.

[0088] As used in this disclosure, the term "extension arm" refers to a nucleotide sequence component of a pegRNA that provides multiple functions, including a primer binding site and a template for DNA synthesis.

[0089] As used in this disclosure, the term "DNA synthesis template" refers to the region or portion of the extended arm of the pegRNA, which is used as a template strand by the reverse transcriptase of the lead editor to encode a 3' single-stranded DNA flap containing the desired edit, which then replaces the corresponding endogenous DNA strand at the target site through the lead editing mechanism.

[0090] The term "primer binding site" or "PBS" refers to a nucleotide sequence located on the pegRNA as a component of the extension arm (usually at the 3' end of the extension arm) and is used to bind the primer sequence formed after Cas9 nicking of the target sequence by the prime editor.

[0091] As used in the present disclosure, the terms "guide RNA", "gRNA" are specific types of guide nucleic acids, which are generally associated with the Cas protein of CRISPR-Cas9 and associated with Cas9, guiding the Cas9 protein to a specific sequence in the DNA molecule including complementarity with the original spacer of the guide RNA. However, the term also includes equivalent guide nucleic acid molecules, which associate with Cas9 equivalents, homologs, orthologs or paralogs, whether naturally occurring or non-naturally occurring (e.g., engineered or recombinant), and otherwise program Cas9 equivalents to locate to a specific target nucleotide sequence. Cas9 equivalents may include other napDNAbps from any type of CRISPR system (e.g., II, V, VI types), including Cpf1 (V-type CRISPR-Cas system), C2c1 (V-type CRISPR-Cas system), C2c2 (VI-type CRISPR-Cas system) and C2c3 (V-type CRISPR-Cas system). Other Cas equivalents are described in Makarova et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” Science 2016; 353(6299), the contents of which are incorporated herein by reference.

[0092] As used in this disclosure, the term "switch" refers to an interchange of purine nucleobases or an interchange of pyrimidine nucleobases.

[0093] As used in this disclosure, the term "transversion" refers to the interchange of a purine nucleobase with a pyrimidine nucleobase, or vice versa, thus involving the interchange of nucleobases having dissimilar shapes.

[0094] As used in this disclosure, the three letter codes and one letter codes for amino acids are as described in J. biol. chem, 243, p3558 (1968).

[0095] As used in the present disclosure, "addition" of amino acids refers to the addition of amino acids at the C-terminus or N-terminus of an amino acid sequence. As used in the present disclosure, "deletion" of amino acids refers to the deletion of 1, 2 or 3 or more amino acids from an amino acid sequence. As used in the present disclosure, "insertion" of amino acids refers to the insertion of amino acid residues at appropriate positions in an amino acid sequence, and the inserted amino acid residues may be all or partly adjacent to each other, or the inserted amino acids may not be adjacent to each other.

[0096] As used in the present disclosure, amino acid "substitution" refers to the replacement of a certain amino acid residue at a certain position in an amino acid sequence by another amino acid residue; wherein the "substitution" may be a conservative amino acid substitution.

[0097] As used in the present disclosure, "conservative modification", "conservative substitution" or "conservative replacement" refers to the replacement of an amino acid in a protein with another amino acid having similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main chain conformation and rigidity, etc.), so that changes can be made frequently without changing the biological activity of the protein. It is known to those skilled in the art that, in general, single amino acid replacements in non-essential regions of a polypeptide do not substantially change the biological activity (see Watson et al. (1987), Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224, (4th edition)). In addition, replacement of amino acids with similar structure or function is unlikely to destroy biological activity. Exemplary conservative replacements are set forth in the following table "Exemplary amino acid conservative replacements".

[0098] Exemplary conservative amino acid substitutions

[0099]

[0100]

[0101] As another example, amino acids with similar characteristics are shown below:

[0102] Acidic residue Asp(D) and Glu(E) Basic residues Lys(K), Arg(R) and His(H) Hydrophilic uncharged residues Ser(S), Thr(T), Asn(N) and Gln(Q) Aliphatic uncharged residue Gly(G), Ala(A), Val(V), Leu(L) and Ile(I) Nonpolar uncharged residues Cys(C), Met(M) and Pro(P) Aromatic residues Phe(F), Tyr(Y) and Trp(W)

[0103] The terms "coding sequence" or "protein coding sequence" as used interchangeably herein refer to a polynucleotide segment that encodes a protein. This region or sequence has a start codon near the 5' end and a stop codon near the 3' end. A coding sequence may also be referred to as an open reading frame.

[0104] As used in the present disclosure, the term "joint" may refer to a covalent joint (e.g., a covalent bond), a non-covalent joint, a chemical group, or a molecule connecting two molecules or parts (e.g., two components of a protein complex or a ribonucleic acid complex), for example, two domains of a fusion protein, such as a nucleic acid programmable DNA binding protein (e.g., nCas9) and a reverse transcriptase domain. The joint can connect different components or different parts of a lead editor or gene editing system. The joint can be located between or on both sides of two groups, molecules, or other parts, and is connected to each by a covalent bond or a non-covalent interaction, thereby connecting the two. In some embodiments, the joint can be a polynucleotide. In some embodiments, the joint can be a DNA joint. In some embodiments, the joint can be an RNA joint. In some embodiments, the joint can be an amino acid or multiple amino acids (e.g., a peptide or protein). In some embodiments, the length of the joint can be about 5 to 100 amino acids, such as about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, or 90 to 100 amino acids. In some embodiments, the length of the joint can be about 100 to 150, 150 to 200, 200 to 250, 250 to 300, 300 to 350, 350 to 400, 400 to 450, or 450 to 500 amino acids. Longer or shorter joints are also contemplated.

[0105] As used in the present disclosure, the term "protease cleavage site" refers to a site that can be specifically recognized and cut by a protease. Various specific proteases and recognition sites thereof are well known to those skilled in the art and are found in many prior art documents. Those skilled in the art can use a suitable protease cleavage site in the fusion protein according to actual conditions and cut with the corresponding protease. The use of the protease cleavage site can be advantageous, for example, it can be used to excise a signal peptide and / or a tag from the fusion protein, thereby obtaining a mature protein with the activity of the purpose.

[0106] As used in the present disclosure, "self-cleaving peptides", "2A self-cleaving peptides" or "2A peptides" are a class of 18-22 amino acid long, viral, self-cleaving peptides. During the translation process of eukaryotic cells, 2A peptides are able to mediate the cleavage of peptides. Four well-known members of the 2A peptide class are T2A, P2A, E2A and F2A. The T2A peptide was first identified in Theresa asigna virus 2A. The P2A peptide was first identified in porcine teschovirus-1 2A. The E2A peptide was first identified in equine rhinitis A virus. The F2A peptide was first identified in hand, foot and mouth disease virus. The self-cleavage mechanism of the 2A peptide is the result of the ribosome skipping the formation of the glycyl-prolyl peptide bond at the C-terminus of 2A.

[0107] As used in the present disclosure, the term "cleavage" may refer to breaking the phosphodiester bond in a nucleotide chain. The type of break may be a single-strand break or a double-strand break.

[0108] As used in the present disclosure, the terms "complementary" or "hybridized" are used to refer to "polynucleotides" and "oligonucleotides" (which are interchangeable terms referring to nucleotide sequences) in relation to base pairing rules. For example, the sequence "CAGT" is complementary to the sequence "GTCA". Complementarity can be "partial" or "complete". "Partial" complementarity refers to mismatches of one or more nucleic acid bases according to the base pairing rules, and "complete" or "complete" complementarity between nucleic acids refers to each nucleic acid base matching another base under the base pairing rules. The degree of complementarity between nucleic acid chains has an important influence on the efficiency and strength of hybridization between nucleic acid chains. This is particularly important in amplification reactions and detection methods that depend on binding between nucleic acids.

[0109] As used in this disclosure, the term "hybridization" refers to the pairing of complementary nucleic acids using any process by which a nucleic acid strand binds to a complementary strand through base pairing to form a hybridization complex.

[0110] As used in this disclosure, the terms "nucleic acid sequence" and "nucleotide sequence" refer to oligonucleotides or polynucleotides and fragments or portions thereof, and refer to DNA or RNA of genomic or synthetic origin that can be single-stranded or double-stranded, and represent the sense or antisense strand.

[0111] As used in the present disclosure, the terms "sequence identity" and "percentage of identity" refer to the percentage of nucleotides or amino acids that are identical (i.e., identical) between two or more polynucleotides or polypeptides. The sequence identity between two or more polynucleotides or polypeptides can be determined by the following method: the nucleotide or amino acid sequences of the polynucleotides or polypeptides are aligned and the number of positions containing the same nucleotide or amino acid residue in the aligned polynucleotides or polypeptides is scored, and compared with the number of positions containing different nucleotides or amino acid residues in the aligned polynucleotides or polypeptides. The polynucleotides may differ at one position, for example, by containing different nucleotides (i.e., substitutions or mutations) or missing nucleotides (i.e., nucleotide insertions or nucleotide deletions in one or two polynucleotides). The polypeptides may differ at one position, for example, by containing different amino acids (i.e., substitutions or mutations) or missing amino acids (i.e., amino acid insertions or amino acid deletions in one or two polypeptides). Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of amino acid residues in the polynucleotide or polypeptide. For example, the percentage of identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of nucleotides or amino acid residues in the polynucleotide or polypeptide and multiplying by 100.

[0112] Exemplary, two or more sequences or subsequences have a "sequence identity" or "percent identity" of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% nucleotides when compared and aligned with maximum correspondence using a sequence comparison algorithm or measured by visual inspection. In certain embodiments, the sequences are substantially identical over the entire length of any one or both of the compared biopolymers (e.g., polynucleotides).

[0113] The term "vector" refers to a means for introducing a nucleic acid sequence into a cell to produce a transformed cell. Vectors include plasmids, transposons, phages, viruses, liposomes, and episomes. An "expression vector" is a nucleic acid sequence that contains a nucleotide sequence to be expressed in a recipient cell. An expression vector may include additional nucleic acid sequences to promote and / or facilitate expression of the introduced sequence, such as initiation, termination, enhancer, promoter, and secretion sequences.

[0114] As used in this disclosure, the terms "individual" and "subject" are used interchangeably and refer to mammals. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual is a human.

[0115] The methods disclosed herein can be performed in vitro, ex vivo, or in vivo, or the products can exist in an in vitro, ex vivo, or in vivo form. The term "in vitro" refers to experiments using materials, biological substances, cells and / or tissues under laboratory conditions or in culture medium; while the term "in vivo" refers to experiments and procedures using intact multicellular organisms. In some embodiments, the methods performed in vivo can be performed on non-human animals. "Ex vivo" refers to events that exist or occur outside an organism, such as outside a human or animal, such as events that can exist or occur on tissues (e.g., whole organs) or cells taken from an organism.

[0116] As used in the present disclosure, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc, magnesium stearate, calcium or zinc or stearic acid) or solvent encapsulating material, involved in transporting or transporting a compound from one part of the body (e.g., a delivery site) to another part (e.g., an organ, tissue or part of the body). A pharmaceutically acceptable carrier is "acceptable" in the sense that it is compatible with the other ingredients of the formulation and is not harmful to the tissues of the subject (e.g., physiologically compatible, sterile, physiological pH, etc.). Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, and taffeta oil. oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; (22) bulking agents, such as peptides and amino acids; (23) serum components, such as serum albumin, high density lipoprotein (HDL) and low density lipoprotein (LDL); (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances used in pharmaceutical preparations. Wetting agents, coloring agents, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives and antioxidants may also be present in the formulation.Terms such as "excipient", "pharmaceutically acceptable carrier" and the like are used interchangeably herein.

[0117] As used in the present disclosure, the term "effective amount" refers to the amount of a bioactive agent sufficient to cause a desired biological response. For example, in some embodiments, an effective amount of a lead editor or a gene editing system may refer to an amount of a lead editor or a gene editing system sufficient to induce a mutation in a target site specifically bound by a lead editor or a gene editing system mutated. As will be appreciated by those skilled in the art, the effective amount of an agent, such as a lead editor, a gene editing system, a polynucleotide, etc., may vary with various factors, such as the desired biological response, such as the specific allele, genome, or target site to be edited, the targeted cells or tissues, and the agents used.

[0118] The terms "treatment", "treatment" refer to clinical interventions intended to reverse, alleviate, delay the onset of, or inhibit the progression of a disease or disorder or one or more symptoms thereof, as described herein. As used in the present disclosure, the terms "treatment", "treatment" refer to clinical interventions intended to reverse, alleviate, delay the onset of, or inhibit the progression of a disease or disorder or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have been formed and / or after the disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, for example, to prevent or delay the onset of symptoms or to inhibit the onset or progression of a disease. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., in view of the history of symptoms and / or in view of genetic or other susceptibility factors). Treatment may also be continued after the symptoms subside, for example, to prevent or delay their recurrence.

[0119] <Pilot Editor>

[0120] In some aspects of the present disclosure, a lead editor is provided, which comprises a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase, and a single-stranded DNA annealing protein (SSAP).

[0121] In some specific embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) and the reverse transcriptase form a fusion protein. In some optional embodiments, the fusion protein comprises the structure NH2-[napDNAbp]-[reverse transcriptase]-COOH; or NH2-[reverse transcriptase]-[napDNAbp]-COOH. In these embodiments, when the lead editor is used, the nucleic acid programmable DNA binding protein (napDNAbp) and the reverse transcriptase can be co-introduced into the subject / cell with the single-stranded DNA annealing protein (SSAP), for example, by expressing the fusion protein and expressing different expression vectors of SSAP.

[0122] In other specific embodiments, nucleic acid programmable DNA binding protein (napDNAbp), reverse transcriptase and single-stranded DNA annealing protein (SSAP) form a fusion protein. In some optional embodiments, the fusion protein comprises the structure NH2-[napDNAbp]-[reverse transcriptase]-[SSAP]-COOH; or NH2-[reverse transcriptase]-[napDNAbp]-[SSAP]-COOH.

[0123] It is to be understood that, as will be described in detail below, any two elements in the above fusion protein may further comprise one or more of an optional linker, a protease cleavage site, a 2A self-cleaving peptide and a nuclear localization sequence.

[0124] Single-stranded DNA annealing protein (SSAP)

[0125] In some embodiments, the single-stranded DNA annealing protein (SSAP) can be a SSAP from a eukaryote, a prokaryote, and / or a bacteriophage.

[0126] In some optional embodiments, the SSAP is from humans, Arcobacter porcinus, Salmonella enterica, Vibrio phage, Delftia acidovorans, Roseburia, Streptococcus, Paenibacillus, Clostridium, Erysipelothrix, Geobacillus, Lactobacillus, Brochothrix, etc., but are not limited to these.

[0127] In other embodiments, the single-stranded DNA annealing protein (SSAP) can be a SSAP from the RecT, RAD52, ERF, Sak3 and / or Gp2.5 family.

[0128] SSAPs that can be used in the present invention are also described in Iyer, Lakshminarayan M et al. "Classification and evolutionary history of the single-strand annealing proteins, RecT, Redbeta, ERF and RAD52." BMC genomics vol.3(2002):8. and Steczkiewicz, Kamil et al. "Expanding Diversity of Firmicutes Single-Strand Annealing Proteins:A Putative Role of Bacteriophage-Host Arms Race." Frontiers in microbiology vol.12 644622.20Apr.2021., which are incorporated herein by reference.

[0129] In some preferred embodiments, the SSAP is from Homo sapiens, Arcobacter porcinus, Salmonella enterica, Vibrio phage, Delftia acidovorans or Roseburia.

[0130] In other preferred embodiments, the SSAP is from the RAD52 family, the Sak3 family or the ERF family. In some specific embodiments, in the present invention, hRAD52, SSAPi1 and SSAPi2 belong to the RAD52 family SSAPs, SSAPi3 belongs to the Sak3 family SSAPs, and SSAPi4 and SSAPi-5 belong to the ERF family SSAPs.

[0131] In some specific embodiments, the SSAP is human hRAD52 (RAD52 family SSAPs), which comprises the amino acid sequence shown in SEQ ID NO:1, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:1.

[0132] In some specific embodiments, the SSAP is SSAPi1 (RAD52 family SSAPs) from Arcobacter porcinus, which comprises the amino acid sequence shown in SEQ ID NO:2, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:2.

[0133] In some specific embodiments, the SSAP is SSAPi2 (RAD52 family SSAPs) derived from Salmonella enterica, which comprises the amino acid sequence shown in SEQ ID NO:3, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:3.

[0134] In some specific embodiments, the SSAP is SSAPi3 (Sak3 family SSAPs) derived from Vibrio phage, which comprises the amino acid sequence shown in SEQ ID NO:4, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:4.

[0135] In some specific embodiments, the SSAP is SSAPi4 (ERF family SSAPs) from Delftia acidovorans, which comprises the amino acid sequence shown in SEQ ID NO:5, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:5.

[0136] In some specific embodiments, the SSAP is SSAPi5 (ERF family SSAPs) from Roseburia, which comprises the amino acid sequence shown in SEQ ID NO:6, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:6.

[0137] The amino acid sequence of SSAP is shown in Table 1.

[0138] Table 1:

[0139]

[0140] Nucleic acid programmable DNA binding protein ( napDNAbp)

[0141] In some embodiments, the napDNAbp has nickase activity.

[0142] In some optional embodiments, the napDNA bp is selected from catalytically impaired (e.g., nuclease inactive) Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, Argonaute protein or variants thereof.

[0143] In some preferred embodiments, the napDNAbp is a Cas9 nickase (nCas9) or a variant thereof.

[0144] In some specific embodiments, the napDNAbp is SpCas9 or a variant thereof. In some more specific embodiments, the napDNAbp is wild-type SpCas9. In other specific embodiments, the napDNAbp is a Cas9 variant and comprises at least one mutation in the RuvC domain and / or the HNH domain (e.g., mutations in D10, H840, H983, D986 or E762, as described in WO 2020 / 191234 A1, the entire contents of which are incorporated herein by reference). For other napDNAbps that can be used, see WO 2020 / 191234 A1.

[0145] In some specific embodiments, the napDNAbp comprises the amino acid sequence shown in SEQ ID NO:7, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:7.

[0146] Exemplarily, the amino acid sequence of napDNAbp is shown in Table 2.

[0147] Table 2:

[0148]

[0149]

[0150] Reverse transcriptase

[0151] In some embodiments, the reverse transcriptase may employ a reverse transcriptase as disclosed in WO 2020 / 191234 A1 (which is incorporated herein by reference).

[0152] In some specific embodiments, the napDNAbp and reverse transcriptase portions in the lead editor of the present disclosure can use a fusion protein of the two in the lead editing (PE) system, as disclosed in WO 2020 / 191234 A1, wherein the PE system uses a fusion protein comprising a catalytically impaired Cas9 nickase and a wild-type (PE1) or engineered (PE2) mouse leukemia virus (MMLV) reverse transcriptase (RT).

[0153] More preferably, the reverse transcriptase comprises the amino acid sequence shown in SEQ ID NO:8, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:8.

[0154] Exemplarily, the amino acid sequence of the reverse transcriptase is shown in Table 3.

[0155] Table 3:

[0156]

[0157] Linkers, protease cleavage sites and 2A self-cleaving peptides

[0158] In some embodiments, the lead editor further comprises a linker and / or a protease cleavage site.

[0159] In some embodiments, linkers and / or protease cleavage sites can be used to connect any two elements in a lead editor.

[0160] In some exemplary embodiments, linkers and / or protease cleavage sites can be used to connect nucleic acid programmable DNA binding protein (napDNAbp), reverse transcriptase and / or single-stranded DNA annealing protein (SSAP).

[0161] In some exemplary embodiments, linkers and / or protease cleavage sites can be used to connect a nuclear localization sequence as described in detail below to the lead editor, for example, to the N-terminus and / or C-terminus of a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase, a single-stranded DNA annealing protein (SSAP), or a 2A self-cleaving peptide.

[0162] In the present invention, specific linkers that can be used can refer to linkers disclosed in WO 2020 / 191234 A1, such as but not limited to (GGGGS)n, (GGS)n, (SGGS)n, etc. In some specific embodiments, the linker can be selected from SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 20), SGGS (SEQ ID NO: 31), GSG.

[0163] In some exemplary embodiments, the protease cleavage site comprises a furin cleavage site, the sequence of which is: RAKR (SEQ ID NO: 32).

[0164] In some preferred embodiments, a 2A self-cleavage peptide is included between napDNAbp and SSAP or between reverse transcriptase and SSAP, preferably, a P2A self-cleavage peptide is included.

[0165] Amino acid sequence of P2A (SEQ ID NO:9): ATNFSLLKQAGDVEENPGP.

[0166] nuclear localization sequence

[0167] The terms "nuclear localization sequence", "nuclear localization signal (NLS)" refer to an amino acid sequence that promotes protein import into the nucleus. Nuclear localization sequences are known in the art and are described in, for example, Plank et al. International PCT Application, PCT / EP2000 / 011690, filed on November 23, 2000, published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, the NLS is an optimized NLS, such as described by Koblan et al., Nature Biotech.2018doi:10.1038 / nbt.4172.

[0168] In some embodiments of the present disclosure, the lead editor provided by the present disclosure may include one or more nuclear localization sequences, which help promote protein translocation into the nucleus. Such sequences are well known in the art.

[0169] In various embodiments, the lead editor disclosed herein further comprises one or more, preferably at least two nuclear localization sequences. In certain embodiments, the lead editor comprises at least two nuclear localization sequences. In embodiments with at least two nuclear localization sequences, the nuclear localization sequences may be the same nuclear localization sequences or may be different nuclear localization sequences.

[0170] In some embodiments, the location of the nuclear localization sequence fusion can be at the N-terminus, the C-terminus, or within the sequence of the prime editor.

[0171] Exemplarily, in the case where a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase, and a single-stranded DNA annealing protein (SSAP) form a fusion protein, the nuclear localization sequence can be fused to the N-terminus, C-terminus, or within the sequence of the fusion protein, for example, inserted between napDNAbp and the reverse transcriptase, or inserted between the reverse transcriptase and the SSAP.

[0172] In the case where the nucleic acid programmable DNA binding protein (napDNAbp) and reverse transcriptase form a fusion protein, the nuclear localization sequence can be fused to the N-terminus, C-terminus of the fusion protein, or within the sequence of the fusion protein, for example, inserted between napDNAbp and reverse transcriptase.

[0173] The nuclear localization sequence can be any known nuclear localization sequence in the art. The nuclear localization sequence can be any naturally occurring nuclear localization sequence, or any non-naturally occurring nuclear localization sequence (eg, a nuclear localization sequence having one or more desired mutations).

[0174] Exemplarily, the nuclear localization sequence that can be used is as follows:

[0175] KRTADGSEFESPKKKRKV(SEQ ID NO:21);

[0176] KRTADGSEFEPKKKRKV(SEQ ID NO:22);

[0177] SPKKKRKV (SEQ ID NO: 23).

[0178] In some specific embodiments, the lead editor comprises one or more of the following sequences:

[0179] (i) an amino acid sequence as shown in any one of SEQ ID NOs: 10 to 15;

[0180] (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15, and which retains the activity of the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15;

[0181] (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of any one of SEQ ID NOs: 10 to 15, and which retains the activity of the amino acid sequence of any one of SEQ ID NOs: 10 to 15; or,

[0182] (iv) an amino acid sequence encoded by a nucleotide sequence, which hybridizes with a polynucleotide sequence encoding the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15 under stringent conditions, and the amino acid sequence retains the activity of the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15, wherein the stringent conditions are medium stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

[0183] In the disclosure, the expression "retaining activity" can be the activity of the lead editor that completely retains the original sequence (for example, the activity of binding to gRNA, nuclease activity, reverse transcriptase activity, single-stranded DNA annealing protein, etc.), or it can be the activity of the lead editor that partially retains the original sequence, for example, retaining 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% of the activity. In other embodiments, a lead editor with a modified sequence, such as a lead editor with an amino acid substituted sequence, may also have an activity higher than that of a lead editor with an original sequence.

[0184] In the present disclosure, "moderate stringency conditions", "moderate-high stringency conditions", "high stringency conditions" or "very high stringency conditions" describe conditions for nucleic acid hybridization and washing. Guidance for conducting hybridization reactions is found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6, which is incorporated herein by reference. Aqueous and non-aqueous methods are described in this document, and either can be used. For example, specific hybridization conditions are as follows: (1) low stringency hybridization conditions are in 6× sodium chloride / sodium citrate (SSC) at about 45°C, followed by two washes in 0.2×SSC, 0.1% SDS at at least 50°C (for low stringency conditions, the washing temperature can be increased to 55°C); (2) moderate stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 60°C; (3) high stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 65°C and preferably; (4) very high stringency hybridization conditions are 0.5 M sodium phosphate, 7% SDS at 65°C, followed by one or more washes in 0.2×SSC, 1% SDS at 65°C.

[0185] The amino acid sequence of the lead editor provided in the present disclosure is shown in Table 4 below.

[0186] Table 4:

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194] <Improving the editing activity of fusion proteins>

[0195] In some aspects of the present disclosure, there is provided a use of a single-stranded DNA annealing protein (SSAP) for improving the editing activity of a fusion protein, wherein the fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase.

[0196] In other aspects of the present disclosure, a method for increasing the editing activity of a fusion protein is provided, comprising the step of co-administering the fusion protein with a single-stranded DNA annealing protein (SSAP), wherein the fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase.

[0197] In some embodiments, the fusion protein can be a fusion protein formed by a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase as described in the <Lead Editor> section above. In some optional embodiments, the fusion protein comprises the structure NH2-[napDNAbp]-[reverse transcriptase]-COOH; or NH2-[reverse transcriptase]-[napDNAbp]-COOH.

[0198] In some embodiments, the fusion protein may be any lead editor disclosed in WO 2020 / 191234 A1. In some specific embodiments, the fusion protein is PE2 disclosed in WO 2020 / 191234.

[0199] In some embodiments, the fusion protein is co-administered with the single-stranded DNA annealing protein (SSAP), and the nucleic acid programmable DNA binding protein (napDNAbp) and the reverse transcriptase form a fusion protein and the single-stranded DNA annealing protein (SSAP) are co-introduced into the subject / cell, for example, by expressing the fusion protein and expressing SSAP in different expression vectors. In other embodiments, the fusion protein is co-administered with the single-stranded DNA annealing protein (SSAP), and the fusion protein and the single-stranded DNA annealing protein (SSAP) are further fused and constructed into the same expression vector.

[0200] In some embodiments, the single-stranded DNA annealing protein (SSAP) is a single-stranded DNA annealing protein (SSAP) as described in the <Lead Editor> section above.

[0201] <Gene Editing System>

[0202] In some aspects of the present disclosure, a gene editing system is provided, comprising:

[0203] (i) a lead editor as described above in the present disclosure; and

[0204] (ii) Prime editing guide RNA (pegRNA).

[0205] Prime editing guide RNA

[0206] In some embodiments, the prime editing guide RNA (pegRNA; or referred to as guide editing guide RNA) can bind to the prime editor (e.g., napDNAbp or a fusion protein comprising napDNAbp therein) and guide the prime editor (e.g., napDNAbp or a fusion protein comprising napDNAbp therein) to the target DNA sequence. In some embodiments, the pegRNA can form a complex with the prime editor (e.g., napDNAbp or a fusion protein comprising napDNAbp therein) and the target DNA sequence.

[0207] In some embodiments, the pegRNA comprises a spacer sequence, a gRNA scaffold, and at least one DNA extension arm. In some embodiments, the DNA extension arm comprises a DNA synthesis template (DNA synthesis template; also known as a reverse transcription template, RT template) and a primer binding site (primer binding site, PBS).

[0208] The guide RNA or pegRNA may contain various structural elements, including but not limited to:

[0209] Spacer sequence - a sequence in the guide RNA or pegRNA (with a length of approximately 20 nt) that binds to the protospacer in the target DNA.

[0210] gRNA core (or gRNA scaffold or backbone sequence) - refers to the sequence within the gRNA responsible for Cas9 binding, which does not include the 20 bp spacer / targeting sequence used to guide Cas9 to the target DNA.

[0211] Extension arm - a single-stranded extension at the 3′ or 5′ end of the pegRNA that contains a primer binding site and a DNA synthesis template sequence that encodes a single-stranded DNA flap containing the genetic change of interest by a polymerase (e.g., reverse transcriptase) and then integrates into the endogenous DNA by displacing the corresponding endogenous strand, thereby installing the desired genetic change.

[0212] Transcription Terminator - A guide RNA or pegRNA may contain a transcription termination sequence at the 3' end of the molecule.

[0213] Based on the disclosure in this article and WO 2020 / 191234 A1, the corresponding lead editing guide RNA can be designed in combination with the target DNA sequence and the specific sequence to be edited.

[0214] In the present disclosure, the exemplary structure of PegRNA is as follows Figure 1 As shown in B.

[0215] In some specific embodiments, pegRNA can bind to the lead editor (e.g., napDNAbp or a fusion protein comprising napDNAbp therein) and guide the lead editor to the target DNA sequence by forming a complex with the lead editor and the target DNA sequence. In some embodiments, pegRNA hybridizes with the target DNA chain and produces a single-stranded DNA flap containing the desired nucleotide changes at the nick site. After identifying the target site, the lead editor and the PegRNA complex will cut a gap in the target DNA chain containing PAM, and use the gapped chain as a primer to directly reverse transcribe the RT template of pegRNA into genomic DNA.

[0216] After reverse transcription, the newly synthesized 3' flap containing the editing sequence invades the adjacent DNA to replace the redundant 5' flap sequence. In some embodiments, the single-stranded DNA flap replaces the target DNA strand that has been nicked. In some embodiments, the relative unedited DNA strand is repaired using the edited DNA strand as a template. In some embodiments, SSAP catalyzes the recombination of the single-stranded DNA flap replacement. In some embodiments, the replaced DNA sequence is excised by a nuclease.

[0217] Typically, the prime editing system provides at least two opportunities for cellular DNA repair to block the desired edit and restore the DNA sequence to its original form: during annealing and ligation of the 3' flap, and during heteroduplex separation. Applicants report a surprising enhancement of target gene editing efficiency during annealing, recombination or ligation by using the disclosed prime editing system incorporating specific SSAPs, as described in the Examples.

[0218] <Polynucleotide>

[0219] The present disclosure provides an isolated polynucleotide encoding the above-mentioned lead editor or encoding the above-mentioned gene editing system.

[0220] In some specific embodiments, the polynucleotide comprises one or more of the following:

[0221] i) a nucleotide sequence encoding the above-mentioned lead editor or the lead editor in the above-mentioned gene editing system; and, ii) a nucleotide sequence encoding the lead editing guide RNA in the above-mentioned gene editing system.

[0222] In some embodiments, the nucleotide sequence of the encoded lead editor is codon optimized. This type of optimization may require mutation of the nucleotide sequence encoding the lead editor to mimic the codon preference of the intended host organism or cell while encoding the same protein.

[0223] In some embodiments, the polynucleotide encoding the above-mentioned lead editor or the lead editor in the above-mentioned gene editing system can be a polynucleotide encoding a fusion protein of nucleic acid programmable DNA binding protein (napDNAbp), reverse transcriptase and single-stranded DNA annealing protein (SSAP).

[0224] In some embodiments, the polynucleotide encoding the above-mentioned lead editor or the lead editor in the above-mentioned gene editing system may include a polynucleotide encoding a fusion protein of a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase and a polynucleotide encoding a single-stranded DNA annealing protein (SSAP).

[0225] In some embodiments, the nucleotide sequence encoding the above-mentioned lead editor or the lead editor in the above-mentioned gene editing system may include a polynucleotide encoding a nucleic acid programmable DNA binding protein (napDNAbp), a polynucleotide encoding a reverse transcriptase, and a polynucleotide encoding a single-stranded DNA annealing protein (SSAP).

[0226] <Carrier>

[0227] The present disclosure provides a vector comprising the above-mentioned polynucleotide.

[0228] In some specific embodiments, the carrier comprises one or more of the following:

[0229] (i) a polynucleotide encoding the above-mentioned lead editor or the lead editor in the above-mentioned gene editing system; and,

[0230] (ii) A polynucleotide encoding the lead editing guide RNA in the above gene editing system.

[0231] In some embodiments, the above (i) to (ii) may be in the same vector. In other embodiments, the above (i) to (ii) may be in different vectors.

[0232] In some embodiments, polynucleotides encoding the nucleic acid programmable DNA binding protein (napDNAbp), reverse transcriptase, and single-stranded DNA annealing protein (SSAP) in the lead editor can also be in the same or different vectors.

[0233] In some embodiments, the vector is an expression vector, more specifically a recombinant expression vector. Suitable expression vectors include viral expression vectors (e.g., viral vectors based on the following viruses, vaccinia virus, polio virus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, human immunodeficiency virus, retroviral vectors (e.g., murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous sarcoma virus, Harvey sarcoma virus, avian leukemia virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus), etc.

[0234] Depending on the host / vector system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, and the like may be used in the expression vector.

[0235] Methods for introducing nucleic acid into host cells are known in the art, and any convenient method can be used to introduce nucleic acid (e.g., expression construct) into cells. Suitable methods include, for example, viral infection, transfection, liposome transfection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, etc.

[0236] <Cell>

[0237] The present disclosure provides a cell comprising one or more of the following:

[0238] (a) the above-mentioned prime editor;

[0239] (b) the above-mentioned gene editing system;

[0240] (c) the polynucleotide described above; and,

[0241] (d) The above-mentioned vector.

[0242] The cell can be any of a variety of cells, including, for example, in vitro cells, in vivo cells, ex vivo cells, primary cells, cancer cells, animal cells, plant cells, algae cells, fungal cells, and the like.

[0243] In some embodiments, the cell is a receptor for the lead editor / gene editing system provided by the present disclosure, which may also be referred to as a "host cell" or a "target cell". The host cell or target cell may be a receptor for the lead editor / gene editing system provided by the present disclosure. The host cell or target cell may be a receptor for the lead editor / gene editing system provided by the present disclosure. The host cell or target cell may be a receptor for a single component in the lead editor / gene editing system provided by the present disclosure.

[0244] In some specific embodiments, non-limiting examples of cells include: prokaryotic cells, eukaryotic cells, bacterial cells, archaeal cells, cells of unicellular eukaryotic organisms, protozoan cells, cells from plants, algal cells, fungal cells, animal cells, cells from invertebrates, cells from vertebrates, cells from mammals (e.g., ungulates; rodents; non-human primates; humans; cats; dogs, etc.), etc. In some cases, the cell is a cell that is not derived from a natural organism (e.g., the cell can be a synthetic cell; also known as an artificial cell).

[0245] <Pharmaceutical Composition and Kit>

[0246] The present disclosure provides a pharmaceutical composition comprising one or more of the following:

[0247] (A) The above-mentioned prime editor;

[0248] (B) The gene editing system described above;

[0249] (C) the above-mentioned polynucleotide;

[0250] (D) the above-mentioned vector; and,

[0251] (E) The above cells.

[0252] In some optional embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0253] In some embodiments, the pharmaceutically acceptable carrier may be a delivery carrier, such as a lipid, a cationic lipid or other polymers having drug delivery function.

[0254] The present disclosure provides a reagent or kit comprising one or more of the following:

[0255] (A) The above-mentioned prime editor;

[0256] (B) The gene editing system described above;

[0257] (C) the above-mentioned polynucleotide;

[0258] (D) the above-mentioned vector; and,

[0259] (E) The above cells.

[0260] In some specific embodiments, the kit may be a disease treatment kit. In other specific embodiments, the kit may be a kit for target nucleic acid modification.

[0261] <Method and use of modifying target nucleic acid>

[0262] The present disclosure provides a method for modifying a target nucleic acid, the method comprising contacting the target nucleic acid with a lead editor provided by the present disclosure, a gene editing system provided by the present disclosure, a polynucleotide provided by the present disclosure, a vector provided by the present disclosure, a cell provided by the present disclosure, a pharmaceutical composition provided by the present disclosure, or a kit provided by the present disclosure. In some embodiments, the contact results in modification of the target nucleic acid by the lead editor or gene editing system. The present disclosure also provides the use of the lead editor provided by the present disclosure, the gene editing system provided by the present disclosure, the polynucleotide provided by the present disclosure, the vector provided by the present disclosure, and the cell provided by the present disclosure in the preparation of a reagent for modifying a target nucleic acid.

[0263] In some specific embodiments, the modification is a change in a nucleotide in the target nucleic acid. In some specific embodiments, the nucleotide change can be a single nucleotide substitution (e.g., transition or transversion change), deletion or insertion.

[0264] In some specific embodiments, the nucleotide change can be (1) a G to T substitution, (2) a G to A substitution, (3) a G to C substitution, (4) a T to G substitution, (5) a T to A substitution, (6) a T to C substitution, (7) a C to G substitution, (8) a C to T substitution, (9) a C to A substitution, (10) an A to T substitution, (11) an A to G substitution, or (12) an A to C substitution.

[0265] In some specific embodiments, the nucleotide change can be a conversion of (1) a G:C base pair to a T:A base pair, (2) a G:C base pair to an A:T base pair, (3) a G:C base pair to a C:G base pair, (4) a T:A base pair to a G:C base pair, (5) a T:A base pair to an A:T base pair, (6) a T:A base pair to a C:G base pair, (7) a C:G base pair to a G:C base pair, (8) a C:G base pair to a T:A base pair, (9) a C:G base pair to an A:T base pair, (10) an A:T base pair to a T:A base pair, (11) an A:T base pair to a G:C base pair, or (12) an A:T base pair to a C:G base pair.

[0266] In some specific embodiments, the nucleotide change can be an insertion. In some cases, the length of the insertion is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides.

[0267] In some specific embodiments, the nucleotide change can be a deletion. In certain other cases, the length of the deletion is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides.

[0268] In some specific embodiments, the contacting occurs in vitro or in vivo. In some specific embodiments, the contacting occurs inside a cell or outside a cell.

[0269] In some specific embodiments, the cell is a eukaryotic cell or a prokaryotic cell.

[0270] In some more specific embodiments, the cell is selected from the group consisting of: plant cells, fungal cells, mammalian cells, reptile cells, insect cells, avian cells, fish cells, parasite cells, arthropod cells, invertebrate cells, vertebrate cells, rodent cells, mouse cells, rat cells, primate cells, non-human primate cells and human cells.

[0271] <Methods and uses for treating diseases>

[0272] The present disclosure provides a method for preventing and / or treating a disease related to or caused by a gene mutation, comprising administering to a subject a therapeutically effective amount of a lead editor, a gene editing system, a polynucleotide, a vector, a cell, a pharmaceutical composition or a kit described in the present disclosure. The gene mutation can be corrected by, for example, a lead editor or a gene editing system provided herein.

[0273] The present disclosure also provides use of the lead editor, gene editing system, polynucleotide, vector, cell, pharmaceutical composition or kit described in the present disclosure in the preparation of a drug for preventing and / or treating diseases related to or caused by gene mutations.

[0274] Nucleotide changes produced by the lead editor or gene editing system provided herein correct disease-related genes. Exemplary, disease-related genes may be associated with a monogenic disorder selected from the group consisting of adenosine deaminase (ADA) deficiency; alpha-1 antitrypsin deficiency; cystic fibrosis; Duchenne muscular dystrophy; galactosemia; hemochromatosis; Huntington's disease; maple syrup urine disease; Marfan syndrome; neurofibromatosis type 1; congenital pachyonychia; phenylketonuria; severe combined immunodeficiency; sickle cell disease; Stevens-Lee-Ou syndrome; and Tay-Sachs disease. In other embodiments, disease-related genes may be associated with polygenic disorders selected from the group consisting of heart disease; hypertension; Alzheimer's disease; arthritis; diabetes; cancer; and obesity.

[0275] The present disclosure also provides the use of the lead editor, gene editing system, polynucleotide, vector, cell or pharmaceutical composition described in the present disclosure in the preparation of a drug for preventing and / or treating diseases related to or caused by gene mutations.

[0276] Example

[0277] The embodiments of the present disclosure will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present disclosure and should not be considered to limit the scope of the present disclosure. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0278] Experimental methods

[0279] 1. Cell Culture

[0280] The HEK 293T or modified HEK 293T cells used in this experiment were cultured in DMEM medium (10% FBS, 1% P / S double antibody, 0.1% mycoplasma removal reagent) in a 37° C., 5% CO 2 incubator.

[0281] 2. Cell transformation

[0282] Construction of mCherry-reporter cell line: 5'LTR-CMV promoter-frameshiftmCherry-Puro-3'LTR plasmid was constructed, lentivirus carrying CMV promoter-frameshift mCherry-Puro was produced, and HEK 293T cells were infected with an MOI of 0.3, and then screened with puromycin (Puromycin), and single cell clones were selected for culture.

[0283] The specific sequence of the lentiviral vector used is as follows (SEQ ID NO: 16):

[0284]

[0285]

[0286]

[0287]

[0288] Among them, the single underlined part is the protospacer; the double underlined part is the frameshift mCherry.

[0289] 3. Cell Transfection

[0290] Plate the cells one day before transfection, and when the cell density reaches 60%-80% on the second day, co-transfect the cells with 1000ng PE2 or PE2-SSAPs plasmid and 500ng pegRNA plasmid using Lipofectamine 3000. Collect the cells 3 days after transfection and analyze the fluorescence intensity by flow cytometry, or extract DNA for NGS sequencing.

[0291] 4. Targeted Amplicon Sequencing

[0292] After extracting the cell genome using the Universal Column Genomic DNA Extraction Kit (CW2298M) from Kangwei Century, primer design and targeted amplicon library amplification were performed according to the user manual of Novasek PE150 of the Illumina platform. The PCR product was recovered using 0.9x Agencourt AMPure XP (Beckman, A63881), the library concentration was measured using Qubit 4 (Thermo, Q33238), and the library fragment distribution was analyzed using the Agilent 4150 TapeStation system. Finally, the samples were sent to Novogene for high-throughput sequencing using the Illumina Novasek PE150 method and the sequencing results were analyzed using CRISPResso2.

[0293] Example 1: Design and construction of PE2-SSAPs system

[0294] In this example, a mCherry-reporter stable cell line was constructed (as described in the experimental method section). Due to the presence of a 1 bp deletion frameshift, mCherry was not expressed. A pegRNA was designed to target the protospacer sequence at the 5' end of the mCherry sequence. At the same time, the reverse transcription template of the pegRNA had a 1 bp insertion. If the gene editing system (PE2 system, the gene editing system constructed in this example) was correctly edited, the mCherry reading frame would return to normal, mCherry would be expressed, and the proportion of mCherry-positive cells analyzed by flow cytometry was the correct editing efficiency ( Figure 1 A in Figure 1 B).

[0295] In order to improve the editing efficiency of the existing PE2 system, this embodiment connects 6 SSAPs proteins to the 3' end of PE2 (a fusion protein of a nucleic acid programmable DNA binding protein and a reverse transcriptase, PE2 disclosed in WO2020 / 191234) through a 2A peptide P2A, and fusion-expresses them, namely, human hRAD52, Arcobacter porcinus-derived SSAPi1, Salmonella enterica-derived SSAPi2, Vibrio phage-derived SSAPi3, Delftia acidovorans-derived SSAPi4, and Roseburia-derived SSAPi5. The constructed gene editing systems are named PE2-hRAD52, PE2-SSAPi1, PE2-SSAPi2, PE2-SSAPi3, PE2-SSAPi4, and PE2-SSAPi5, respectively. Figure 1 C), the specific sequence is shown in Table 4.

[0296] As a control, the same method was used to express the recombinase RecA from Escherichia coli at the 3' end of PE2 through 2A peptide P2A connection fusion. The amino acid sequence of the recombinase RecA is shown below (SEQ ID NO:33):AIDENKQKALAAALGQIEKQFGKGSIMRLGEDRSMDVETISTGSLSLDIALGAGGLPMGRIVEIYGPESSGKTTLTLQVIAAAQREGKTCAFIDAEHALDPIYARKLGVDIDNLLCSQPDTGEQALEICDALARSGAVDVIVVDSVAALTPKAEIEGEIGDSHMGLAARMMS QAMRKLAGNLKQSNTLLIFINQIRMKIGVMFGNPETTTGGNALKFYASVRLDIRRIGAVKEGENVVGSETRVKVVKNKIAAPFKQAEFQILYGEGINFYGELVDLGVKEKLIEKAGAWYSYKGEKIGQGKANATAWLKDNPETAKEIEKKVRELLLSNPNSTPDFSVDDSEGVAETNEDF

[0297]

[0298] The pegRNA expression vector constructed in this example was synthesized from the GENERAL BIOL gene.

[0299] The specific sequence of the constructed vector expressing pegRNA (SEQ ID NO: 17):

[0300]

[0301]

[0302] Among them, the single underlined part is the spacer sequence (Spacer); the bold + italicized part is the gRNA scaffold (gRNA scaffold, specifically Sp gRNA scaffold); the double underlined part is the 16bp reverse transcription template (16bp RTtemplate); the dotted underline is the 10bp primer binding site (10bp PBS).

[0303] In this example, the constructed vector for expressing PE2 or PE2-SSAPs was synthesized from the gene of GENERAL BIOL.

[0304] The specific sequence of the constructed vector expressing PE2 or PE2-SSAPs is as follows:

[0305] Vector expressing PE2 (SEQ ID NO: 24):

[0306]

[0307]

[0308]

[0309]

[0310]

[0311] Among them, the single underline is Cas9 (H840A); italics + bold are linker sequences; and the double underline is MMLV RT.

[0312] Vector expressing PE2-hRAD52 (SEQ ID NO: 25):

[0313]

[0314]

[0315]

[0316]

[0317]

[0318] Among them, the single underline is Cas9 (H840A); the italic + bold is the linker sequence; the double underline is MMLV RT; the dotted underline is hRAD52; the italic only is the NLS sequence (SV40 NLS / NLS); the bold only is P2A; the gray shaded part is the furin protease cleavage site.

[0319] Vector expressing PE2-RecA: The vector expressing PE2-hRAD52 (SEQ ID NO: 25) is prepared by replacing the hRAD52 portion with the following nucleotide sequence encoding RecA (SEQ ID NO: 35).

[0320]

[0321] Vector expressing PE2-SSAPi1: It can be obtained by replacing the hRAD52 part in the vector expressing PE2-hRAD52 (SEQ ID NO:25) with the following nucleotides encoding SSAPi1 (SEQ ID NO:26).

[0322] ATGTTCGACAAGAAACAGCTGGATATCCTGAACCAGGAGCTGGATATCTCTAGAATCAAGACCAGAGAGAAGGGCAACATCAGCCTGAGCTACATCGAGGGCCACGACGTGATCGAGACAGCCAACAAGGTGTTCGGCTTTGGCAACTGGTCCTACAGCATCAGCAAGCTGGAACACGTCAGCCAGGAACAAAACCAAAATCAAAATCATGTGATCTGTTACAAGGCCATTGTGCAGGTGCTGGTGCACAGCGAGAACCACACCCTGGATATCAGCCGCGAAGATGTGGGCTTTGGAACAGGCGTGGCTAAAACACAGGCTGATGCCCACGAGGGAGCCGCCAAGGAAGCCGTGACCGACGCCCTGAAGCGGGCCATGCGGAGCTTCGGAAATCAGTTCGGCAACAGCCTCTACGACAAGACAAAGAACCACCAGGCCAACAACGAGAGCATTCCTAGCTCTAGCAGCAGACCACAGCAGACCAACTACAGACAGTCCGCCCCTGCTCCTACCGTGACCACCAACCACAACCGGAATATCAAGCAGTCTTATGACCCCTACGAGTACGAGTCTCTGTTCAAGATCGGCCTGGACGTGGTGGAACAGAACGGCTTCCTGATCGTTACAGGCGACGACATCTTCGCCAAGAAGGACAGCATCAAAGCATGCGGCTTCAGATGGGACGGCAAGACCAAGTCCTGGTACAAAGCCATCGAACAGGAGGTGGCC(SEQ ID NO:26)

[0323] Vector expressing PE2-SSAPi2: The vector expressing PE2-hRAD52 (SEQ ID NO: 25) can be obtained by replacing the hRAD52 portion with the following nucleotide sequence encoding SSAPi2 (SEQ ID NO: 27).

[0324] (SEQ ID NO:27)

[0325] Vector expressing PE2-SSAPi3: The vector expressing PE2-hRAD52 (SEQ ID NO: 25) can be obtained by replacing the hRAD52 portion with the following nucleotide encoding SSAPi3 (SEQ ID NO: 28).

[0326] ATGAGCAACGACATCTTTAAGACACTGCATGCCATCAATGTGAACGGCAGAACCGAGAAGAAGGGCAAACTGACCTACCTGAGCTGGGCCTGGGCTTGGGCCGAGGTGTGCAAGATCTACCCCGACGCCAATTATACAGTGGACGAGCACGACGGAAAACCTTACCTCTACGACGAGAACCTGGGCTACCTGGTGTCCACCAAGGTGACCATCGACGGCAAGACCATTCCTATGAGCCTGCCTGTGATGGACGGCGCCAACAACGCCATGAAAAGCGTGCGGTACTCTTATAAGGTTAAGGAATGGGTCGGCGGAAGAGCCACAGGCAACTACATCGATAAGTTCGTGGAACCCGCAACCATGTTTGACATCAACAAGACCATGATGAGATGTCTGGTGAAGAACCTGGCTATGTTCGGCCTGGGACTGTACATCTACGCCGGCGAAGATCTGCCTGAGCCTCCACCTGCTAAGCCCATCAATTTCGATGAAGTGCTGGAAGAATTCGAGGTGGCCGCTGATAAGGCCAAGACCGAGGAAGAGCTGAAGCAGCTGTTCGCCCCAGCCTACAAGACACTGAGCGCCTCTAAGACCCACCAGGCCAAAGCCAAAAACCACTACGACATCCGGAAGAGCGAGATCCAGGTGGGCGAGATG(SEQ ID NO:28)

[0327] Vector expressing PE2-SSAPi4: It can be obtained by replacing the hRAD52 part in the vector expressing PE2-hRAD52 (SEQ ID NO:25) with the following nucleotides encoding SSAPi4 (SEQ ID NO:29).

[0328] ATGAACACCGCCACAGAGGAAATGACCCTGATCGACGTCCCCGTGCAGCAGCAGGCTGTCCCCGCCGTGCAACAGGGCGGCGCTCTGGCCCCTAATAGCCCCGCCGCCATGATGATGGCCGCCATGAGCCAGGGCGCTTCTCTGGAACAGGTGGAAAAGATGATGGACCTGCAAGATAGATGGGAGAAGAAAGAGGCCGAGAAGGCCTACAACGCCGCATTCGCCGCTTTTAAGTCTGAGGCCGTGCGGATTGTGCAGGGCAGAACCGTGACAGACGGACCTCTGAAGGGCAGAGCCTATGCCGAACTGCATGATGTGGTGAAGGCTGTTACACCTGCCCTGTCCAGACACGGACTGAGCGCCAGCTGGCGGCTCTCTAAGGACGAGCCACAGTGGATCGAGATCACCTGCGTGCTGAAGCACATCGGCGGACACAGCGAGAGCGTGTCTATGGGCGGCGCCCCTGATACCGGCGGCGCCAAGAACCAGCTGCAGGCTAGAGCCAGCACCAAGAGCTACCTGGAAAGATACACCCTGAAAGCCATCTGCGGCGTGGCCGAGGGCGGCGACGATGATGACGGCGACGGCGGAGGCACAAGCGACCTGGTGTCCGGCTGGGTGGACTACGCCCTGGCCAGAAAGGGCACCCCTGAGTTCGACGCCGCTTGTAAAAAAGCCAGGGCTGAATTCGATAAGAGCCGGGACGTGGCCAGCCTGAAGGCCTTCAACGCCGCCGTGGCCAAGGGA(SEQIDNO:29)

[0329] Vector expressing PE2-SSAPi5: It can be obtained by replacing the hRAD52 part in the vector expressing PE2-hRAD52 (SEQ ID NO: 25) with the following nucleotides encoding SSAPi5 (SEQ ID NO: 30).

[0330] ATGCAGGAGGAACAGAAAGAGACAGCCGCTGGATCTCCAGTCGCCTCTTTTCAGACAAGAAGGGACAAGCCCATCGAAGTGATGAGCCTGCAGGAGAAGTTCATCGAGCTGCGGCGGCAGATCCCCAGAATCGAGAAGGGCCAACACTCCGAAGAAGTGCCCTACAAGTTTGCCAAGATCGATGATGTGTGGCGGGCCATCACCCCTACAATGAATGAGCTGGGCGTGAACTTCGACATCATCCAGGAGGAAAACGCTCAAATCAAGACCATGAATACCCAGCACGGCGGCCTGATGTTCCTGTACGAGAGCGACCTCACCATGCGCTGGACCAACGCCGACAACGAGGACGATACCGACGAGGCCCAGACCCACGCCATCGCCTGGAACGACGACCCTGCCAAAGCCAAGGGCTCTGCCTGGACCTACGCCATTAAGTACTACCTGTTCGAGAAGTTCAGCATCGACATGGGCGAAACCGATCCTGATATGAAAGGCAAGCCTAGCGCCCAAACCGCCAGCCAGCCTGTGCGGAACGCCGCCGGCAACCAGCAGAGCCAGCAGGGCAACAAGACAGCCCAGTCCGGCCAGAACGGCGCCGAGAAAAAGCTGACAGCTGCCCAGCTGGACAGAATGTATAGAAAGGCCCAGGACGCTGGACTGAGCAAGGAACAGACCGACGGCAGAATCAACTACCTGTACAGCAAGAAACCTGCTGATATGACCAGAGCCGAATACGACGACATCTGCAAGCGGATGGACGATACAGCTAGAGAGCTGAGAAACGGCGGAAATAGACAG(SEQ ID NO:30)

[0331] Example 2: PE2-SSAPs significantly improve the mCherry activation rate of reporter cell lines

[0332] The mCherry-reporter stable cell line was co-transfected with the pegRNA and PE2, PE2-RecA or PE2-SSAPs plasmid (vector) constructed in Example 1, and the activation ratio of mCherry in the reporter cell line was analyzed by flow cytometer 3 days after transfection. It can be seen that the untransfected cells did not express mCherry, and the proportion of mCherry positive cells after PE2 system transfection was about 22%. Compared with PE2 and PE2-RecA, the proportion of PE2-SSAPs activating mCherry expression was higher, and the activation ratios of PE2-hRAD52, PE2-SSAPi1, PE2-SSAPi2, PE2-SSAPi3, PE2-SSAPi4 and PE2-SSAPi5 were 32%, 35%, 33%, 40%, 36% and 43% respectively ( Figure 2 A in Figure 2 B). The activation ratios were 1.42, 1.55, 1.46, 1.77, 1.60 and 1.87 times that of PE2, which were also higher than 30% of PE2-RecA. It can be seen that PE2 fusion expression of SSAPs in mCherry-reporter cell lines can improve the editing efficiency of PE2 target sites, and the improvement effect is better than PE2 fusion expression of RecA.

[0333] Example 3: PE2-SSAPs significantly improve the editing efficiency of the target site in reporter cell lines

[0334] In order to further accurately evaluate the editing efficiency and accuracy of PE2 and PE2-SSAPs for the target site of the reporter cell line, this example extracted the genomic DNA of the reporter cell line 3 days after transfection, and constructed a targeted amplicon library and performed high-throughput sequencing on it. After PE2 editing, a base A will be inserted before the first base at the 5' end of the nCas9 restriction site, and the original sixth base G at the 5' end will be replaced by T. The high-throughput sequencing results show that compared with PE2, the correct editing efficiency of PE2-SSAPs is significantly improved ( Figure 3 ). The statistical results showed that the correct editing efficiency of PE2 was about 19%, and the activation ratios of PE2-hRAD52, PE2-SSAPi1, PE2-SSAPi2, PE2-SSAPi3, PE2-SSAPi4 and PE2-SSAPi5 were 32%, 35%, 28%, 45%, 36% and 43%, respectively ( Figure 4 The activation ratios are 1.70, 1.87, 1.50, 2.45, 1.95 and 2.32 times that of PE2 respectively ( Figure 4B). We also compared the Indels caused by PE2 and PE2-SSAPs near the target site, and the results showed that the Indels levels of PE2 and PE2-SSAPs were very low and almost negligible. In summary, high-throughput sequencing data further proves that PE2-SSAPs can significantly improve the editing efficiency of PE2, while retaining the advantages of high accuracy and safety of the PE2 system.

[0335] Example 4: PE2-SSAPs significantly improve the editing efficiency of endogenous sites in cells

[0336] The results of Examples 2 and 3 show that PE2-SSAPs have higher editing activity in reporter cell lines. Next, this example further verifies its editing efficiency and precision at endogenous gene sites in cells. This example selects the EMX1 and HEK3 gene sites of HEK 293T cells.

[0337] The plasmid expressing PE2 or PE2-SSAPs used in this example was constructed as in Example 1.

[0338] The pegRNA expression vector used in this example was synthesized from GENERAL BIOL genes.

[0339] Specific sequences of pegRNA-expressing vectors used:

[0340] The vector expressing pegRNA-EMX1 can be obtained by replacing the pegRNA part (spacer sequence + gRNA scaffold + reverse transcription template + primer binding site) in the vector expressing pegRNA (SEQ ID NO: 17) with the sequence shown in the following SEQ ID NO: 18.

[0341]

[0342] Among them, the single underlined part is the spacer sequence (Spacer); the bold + italicized part is the gRNA scaffold (gRNA scaffold, specifically Sp gRNA scaffold); the double underlined part is the 16bp reverse transcription template (16bp RTtemplate); the dotted underline is the 13bp primer binding site (13bp PBS).

[0343] The vector expressing pegRNA-HEK3 can be obtained by replacing the pegRNA part (spacer sequence + gRNA scaffold + reverse transcription template + primer binding site) in the vector expressing pegRNA (SEQ ID NO: 17) with the sequence shown in the following SEQ ID NO: 19.

[0344]

[0345] Among them, the single underlined part is the spacer sequence (Spacer); the bold + italicized part is the gRNA scaffold (gRNA scaffold, specifically Sp gRNA scaffold); the double underlined part is the 13bp reverse transcription template (13bp RTtemplate); the dotted underline is the 13bp primer binding site (13bp PBS).

[0346] For the EMX1 site, PE2 editing will replace the first base at the 3' end of the nCas9 restriction site (+1 site) from G to C (+1G to C) ( Figure 5 A in HEK3, after editing, the T at the +1 site mutates to A (+1Tto A). HEK3 contains a SNP (single nucleotide polymorphism) site 9 bp downstream of this site, which is ignored when calculating the editing efficiency ( Figure 5 B in the figure). Targeted amplicon sequencing results showed that for the EMX1 site, the editing efficiency of PE2-SSAPs was increased from 0.5% of PE2 to 2.1% at most, and its overall editing efficiency was 2-4 times that of PE2 ( Figure 5 C in the figure). For the HEK3 site, the editing efficiency increased from 1.4% to 2.9%, and the overall editing efficiency was 1.2-2.1 times that of PE2 ( Figure 5 At the same time, the results showed that the proportion of Indels of PE2-SSAPs at endogenous sites was also very low, retaining the advantage of PE2 in terms of safety ( Figure 5 C in Figure 5 The above results indicate that PE2-SSAPs also exhibit better editing activity than PE2 at endogenous sites in cells and retain the editing accuracy.

[0347] It should be noted that, although the technical solutions of the present disclosure are introduced with specific examples, those skilled in the art will appreciate that the present disclosure should not be limited thereto.

[0348] The embodiments of the present disclosure have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. A lead editor, in, The lead editor comprises a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase, and a single-stranded DNA annealing protein (SSAP).

2. The lead editor according to claim 1, in, The SSAP is a SSAP from a eukaryote, a prokaryote and / or a bacteriophage; and / or, The SSAP is a SSAP from the RecT, RAD52, ERF, Sak3 and / or Gp2.5 family.

3. The lead editor according to claim 1 or 2, in, The SSAP is derived from Homo sapiens, Arcobacter porcinus, Salmonella enterica, Vibriophage, Delftia acidovorans or Roseburia; and / or, The SSAP is from the RAD52 family, the Sak3 family or the ERF family.

4. The lead editor according to any one of claims 1 to 3, in, The SSAP comprises an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 6, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 1 to 6.

5. The lead editor according to any one of claims 1 to 4, in, The napDNAbp has nickase activity; Optionally, the napDNAbp is selected from a catalytically impaired Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, Argonaute protein or a variant thereof; Preferably, the napDNAbp is Cas9 nickase (nCas9) or a variant thereof; More preferably, the napDNAbp comprises the amino acid sequence shown in SEQ ID NO:7, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:

7.

6. The lead editor according to any one of claims 1 to 5, in, The reverse transcriptase comprises the amino acid sequence shown in SEQ ID NO:8, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with SEQ ID NO:

8.

7. The lead editor according to any one of claims 1 to 6, in, The napDNAbp, reverse transcriptase and SSAP form a fusion protein, or the napDNAbp and reverse transcriptase form a fusion protein; Optionally, the fusion protein comprises the structure NH 2 -[napDNAbp]-[reverse transcriptase]-[SSAP]-COOH; or NH 2 -[reverse transcriptase]-[napDNAbp]-[SSAP]-COOH; Optionally, the fusion protein comprises the structure NH 2 -[napDNAbp]-[reverse transcriptase]-COOH; or NH 2 -[Reverse transcriptase]-[napDNAbp]-COOH.

8. The lead editor according to claim 7, in, A 2A self-cleavage peptide is included between the napDNAbp and SSAP or between the reverse transcriptase and SSAP; Preferably, a P2A self-cleavage peptide is included between the napDNAbp and SSAP or between the reverse transcriptase and SSAP.

9. The lead editor according to any one of claims 1 to 8, in, The lead editor comprises one or more of the following sequences: (i) an amino acid sequence as shown in any one of SEQ ID NOs: 10 to 15; (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15, and which retains the activity of the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15; (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of any one of SEQ ID NOs: 10 to 15, and which retains the activity of the amino acid sequence of any one of SEQ ID NOs: 10 to 15; or, (iv) an amino acid sequence encoded by a nucleotide sequence, which hybridizes with a polynucleotide sequence encoding the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15 under stringent conditions, and the amino acid sequence retains the activity of the amino acid sequence shown in any one of SEQ ID NOs: 10 to 15, wherein the stringent conditions are medium stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

10. A gene editing system, in, The gene editing system comprises: (i) the lead editor according to any one of claims 1 to 9; and (ii) Prime editing guide RNA (pegRNA).

11. An isolated polynucleotide, in, The polynucleotide encodes the lead editor as described in any one of claims 1 to 9 or encodes the gene editing system as described in claim 10. A vector comprising the polynucleotide according to claim 11 .

13. A cell comprising one or more of the following: (a) The lead editor according to any one of claims 1 to 9; (b) The gene editing system as claimed in claim 10; (c) the polynucleotide of claim 11; and, (d) The vector according to claim 12.

14. A pharmaceutical composition comprising one or more of the following (A) to (E): (A) The lead editor according to any one of claims 1 to 9; (B) the gene editing system as claimed in claim 10; (C) the polynucleotide according to claim 11; (D) the vector according to claim 12; and (E) the cell according to claim 13; And, optionally, a pharmaceutically acceptable carrier.

15. A kit comprising one or more of the following: (A) The lead editor according to any one of claims 1 to 9; (B) the gene editing system as claimed in claim 10; (C) the polynucleotide according to claim 11; (D) the vector according to claim 12; and (E) The cell according to claim 13.

16. A method for modifying a target nucleic acid, the method comprising the step of contacting the target nucleic acid with a lead editor as described in any one of claims 1 to 9, a gene editing system as described in claim 10, a polynucleotide as described in claim 11, a vector as described in claim 12, a cell as described in claim 13, a pharmaceutical composition as described in claim 14, or a kit as described in claim 15.

17. Use of the lead editor according to any one of claims 1 to 9, the gene editing system according to claim 10, the polynucleotide according to claim 11, the vector according to claim 12 or the cell according to claim 13 in the preparation of a reagent for modifying a target nucleic acid.

18. A method for preventing and / or treating diseases associated with or caused by gene mutations, comprising the step of administering to a subject a therapeutically effective amount of the lead editor as described in any one of claims 1 to 9, the gene editing system as described in claim 10, the polynucleotide as described in claim 11, the vector as described in claim 12, the cell as described in claim 13, the pharmaceutical composition as described in claim 14, or the kit as described in claim 15.

19. Use of the lead editor as described in any one of claims 1 to 9, the gene editing system as described in claim 10, the polynucleotide as described in claim 11, the vector as described in claim 12, the cell as described in claim 13, the pharmaceutical composition as described in claim 14, or the kit as described in claim 15 in the preparation of a drug for treating diseases related to or caused by gene mutations.

20. Use of a single-stranded DNA annealing protein (SSAP) for improving the editing activity of a fusion protein, wherein the fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase.

21. A method for increasing the editing activity of a fusion protein, comprising the step of co-administering the fusion protein with a single-stranded DNA annealing protein (SSAP), wherein the fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase.

Citation Information

Cited By

  • Split-phase nicking enzyme mediated pilot editor and editing system and application of split-phase nicking enzyme mediated pilot editor

    CN122168603A